A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects with Moderately to Severely Active Ulcerative Colitis - Niet van toepassing

Janssen-Cilag0 个研究点目标入组 8 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- Have a clinical diagnosis of ulcerative colitis (UC) at least 3 months prior to screening ;- Have moderately to severely active UC, defined as a baseline (Week 0) Mayo score of 6 to 12 ; including an endoscopy subscore greater than or equal to 2 as determined by a central read of the video endoscopy ;- Current treatment with oral corticosteroids or have a history of failure to respond to, or tolerate, at least 1 of the following therapies oral corticosteroids (including budesonide), 6-mercaptopurine (6-MP), azathioprine (AZA), or anti-tumor necrosis factor therapy or be corticosteroid dependent (ie, an inability to successfully taper corticosteroids without a return of the symptoms of UC ;- Must discontinue 6-MP/AZA for at least 1 week before the first dose of study medication

•- At imminent risk for colectomy ;- Have ulcerative colitis limited to the rectum only or to less than 20 centimeter of the colon ;- Presence of a stoma ;- Presence or history of a fistula ;- History or current diagnosis of active or latent tuberculosis (An exception is made for
•subjects who have a history of latent TB and are currently receiving treatment for latent
•TB) , human immunodeficiency virus, hepatitis C virus or hepatitis B virus infection ;- Have had more than 1 herpes zoster infection or have had any diagnosis disseminated herpes zoster;- Previous treatment with a janus kinase inhibitor (eg, tofacitinib)

发起方